skip to content
Dovepress - Open Access to Scientific and Medical Research
View our mobile site

8838

An update on the safety and efficacy of decitabine in the treatment of myelodysplastic syndromes

Review

(2538) Views  (938) Full article downloads

Authors: Jacqueline S Garcia, Nitin Jain, Lucy A Godley

Published Date February 2010 Volume 2010:3 Pages 1 - 13
DOI: http://dx.doi.org/10.2147/OTT.S7222

Jacqueline S Garcia1, Nitin Jain1, Lucy A Godley1,2

1Section of Hematology/Oncology, Department of Medicine, The University of Chicago, Chicago, IL, USA; 2Cancer Research Center, The University of Chicago, Chicago, IL, USA

Abstract: Myelodysplastic syndromes (MDS) are clonal bone marrow malignancies characterized by peripheral cytopenias and dysplastic changes in the bone marrow with various clinical features. Patients with MDS, in particular those with intermediate-2 (Int-2) and high-risk disease, have a poor prognosis. The mainstay of treatment includes cytoxic chemotherapy and supportive care. Over the last decade, promising results from studies focusing on hypomethylating agents, such as decitabine (5-aza-deoxycytidine) and 5-azacitidine, have led to the expansion of the therapeutic arsenal for MDS. This review presents the current data available on the clinical efficacy and safety profile for decitabine as a treatment for MDS. Although not fully understood, decitabine’s antitumor activity may involve its ability to induce hypomethylation and reactivation of genes responsible for cellular differentiation, stimulate an immune response, induce DNA damage/apoptotic response pathways, and/or augment stem cell renewal. Future studies that use epigenetic therapies that combine hypomethylating agents with histone deacetylase inhibitors (HDACi) and head-to-head comparison studies of decitabine and 5-azacitidine will provide valuable pre-clinical and clinical data, enhancing our understanding of these drugs.

Keywords: decitabine, 5-aza-deoxycytidine, 5-azacitidine, myelodysplastic syndromes








Readers of this article also read:

Evidence-based decision-making within the context of globalization: A “Why–What–How” for leaders and managers of health care organizations
Role of aliskiren in cardio-renal protection and use in hypertensives with multiple risk factors
Age-related disruption of the lamina dura: Evidence in the mandibular horizontal incompletely impacted third molar
CTLA-4 blockade: therapeutic potential in cancer treatments
ABO and rhesus blood group distribution in Kurds
Azacitidine and decitabine have different mechanisms of action in non-small cell lung cancer cell lines
Improvement of adenoviral vector-mediated gene transfer to airway epithelia by folate-modified anionic liposomes
The relationship between deliberate self-harm behavior, body dissatisfaction, and suicide in adolescents: current concepts
Zinc oxide nanoparticles as selective killers of proliferating cells
Cumulative clinical experience from over a decade of use of levofloxacin in community-acquired pneumonia: critical appraisal and role in therapy